Lung Cancer in Non-Smokers: ALK Gene Mutations & Targeted Therapy

44-year-old Ms. Zeng (pseudonym) is a lifelong non-smoker who sought medical attention two years ago due to shortness of breath and a persistent cough. After examination, she was found to have a roughly 5-centimeter tumor in her left lung, surrounding the left main bronchus and left pulmonary artery, with spread to the pleura, indicating stage four lung adenocarcinoma. Ms. Zeng was surprised to be diagnosed with lung cancer, given her non-smoking history. Genetic testing revealed an ALK gene mutation in the tumor, leading her doctors to prescribe a third-generation ALK targeted therapy. While Ms. Zeng experienced mild finger numbness and elevated cholesterol during treatment, these side effects were managed with cholesterol-lowering medication. After five months on targeted therapy, the tumor began to shrink, and after a year, it completely resolved. Currently, Ms. Zeng has been on targeted therapy for over two and a half years, with recent check-ups showing continued tumor control, no recurrence, and she is able to travel and maintain a good quality of life.

Early Lung Cancer Often Lacks Obvious Symptoms, Making it Easy to Overlook

Clinical oncologist Dr. Yuen Chui Yu explains that while smoking is the leading cause of lung cancer, non-smokers can also develop the disease due to factors such as secondhand smoke exposure, air pollution, genetics, a family history of lung cancer, or prolonged exposure to carcinogenic substances like asbestos. Notably, a higher proportion of non-smokers are affected by lung adenocarcinoma in Asia, potentially linked to specific gene mutations and environmental factors, highlighting the importance of awareness even without a smoking history.

Because the lungs have few nerve endings, early-stage lung cancer often presents with subtle symptoms like cough and rapid breathing, which are easily dismissed, leading to most patients being diagnosed at a later stage. Dr. Yuen added that some patients may experience rusty-colored sputum, difficulty breathing, hoarseness, coughing up blood, and occasional chest pain. As the disease progresses, lung cancer can metastasize to other organs, causing more systemic symptoms, including weight loss, loss of appetite, persistent fever, and extreme fatigue. Additionally, when lung cancer spreads to the bones and brain, patients may experience bone pain, headache, dizziness, and weakness in the limbs.

Different Lung Cancer Types Require Different Treatment Approaches

Generally, treating lung cancer begins with understanding its classification to tailor treatment accordingly. Lung cancer is primarily divided into non-small cell lung cancer (NSCLC) and small cell lung cancer, with NSCLC accounting for approximately 85% of cases. NSCLC can be further categorized into three subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Furthermore, NSCLC includes over a dozen gene mutations, with EGFR, KRAS, and ALK being among the most common. In the case of ALK gene mutation lung cancer, patients are often younger, and the majority are non-smokers or very light smokers. This type of tumor tends to be more aggressive and is particularly prone to brain metastasis.

For advanced ALK gene mutation lung cancer, there are currently three generations and four types of oral targeted therapies available. Dr. Yuen noted that first-generation drugs have faster resistance and more side effects and are now less commonly used, with most patients starting with second or third-generation drugs. Studies show that third-generation targeted therapies can extend progression-free survival to over five years and effectively reduce the risk of brain metastasis. Common side effects include edema, elevated cholesterol, and weight gain, with a small number of patients experiencing mood changes or cognitive dysfunction. Therefore, doctors closely monitor patients for side effects during treatment and manage them through dosage adjustments and supportive medications. Dr. Yuen continued, that patients with advanced ALK gene mutation lung cancer can achieve rapid, deep, and durable responses with current targeted therapies, even when diagnosed with large tumors and pleural involvement, extending survival and maintaining quality of life. Given the unique circumstances of each patient, they should discuss appropriate treatment options with their doctor.